New Research Released on Emerald Health Pharmaceuticals (CLOSELY-HELD)

Posted by Karen Goldfarb

November 30, 2021 at 6:22 PM

An Executive Informational Overview (EIO) is now available on Emerald Health Pharmaceuticals Inc., a closely-held clinical-stage biotechnology company developing novel proprietary therapeutic molecules to treat various neurodegenerative, autoimmune, inflammatory, and fibrotic diseases with no current cure. The 74-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Emerald Health Pharmaceuticals Initiation Report

Read More

Topics: biotech, biopharmaceuticals, biotechnology, neurodegenerative, fibrotic, multiple sclerosis, Huntingtons Disease, cannabigerol, SSc, inflammatory, systemic sclerosis, MS, Parkinsons Disease, cannabinoids, cannabidiol

November 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 17, 2021 at 9:28 AM

Crystal Research Associates has issued a 13-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

GeoVax Enters Agreement with PNP Therapeutics for Solid Tumor Treatment

Posted by Karen Goldfarb

October 4, 2021 at 11:13 AM

Crystal Research Associates has issued a 6-page update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ) following its announcement of an Assignment and License Agreement with PNP Therapeutics, Inc. (“PNP”), granting GeoVax exclusive rights to develop and commercialize Gedeptin®, a novel patented product to treat solid tumors. 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

August 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

August 15, 2021 at 6:35 PM

Crystal Research Associates has issued a 15-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

May 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

May 11, 2021 at 3:59 PM

Crystal Research Associates has issued an 16-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

March 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

March 29, 2021 at 2:53 PM

Crystal Research Associates has issued an 14-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

February 2021 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

February 16, 2021 at 10:13 AM

Crystal Research Associates has issued an 11-page Quarterly Update on clinical-stage biotechnology company, GeoVax Labs, Inc. (GOVX-NASDAQ).

 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

New Research Released on Celsion Corporation (CLSN-NASDAQ)

Posted by Karen Goldfarb

December 9, 2020 at 3:35 PM

An Executive Informational Overview (EIO) is now available on Celsion Corporation, a fully integrated biopharmaceutical company focused on developing cancer therapies for difficult-to-treat forms of cancers. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download Celsion Corporation  Initiation Report

Read More

Topics: biotech, immunotherapy, cancer, autoimmune, hepatocellular cancer, GEN-1, ovarian cancer, interleukin-12, IL-12, ThermoDox, primary liver cancer, celsion

November 2020 Update on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

November 11, 2020 at 10:24 AM

Crystal Research Associates has issued a 12-page Quarterly Update on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ).

 

Read More

Topics: immunotherapy, malaria, hemorragic fever, geovax, vaccines, zika, aids/hiv, hbv, covid19, coronovirus

UPDATED BASE REPORT on GeoVax Labs, Inc. (GOVX-NASDAQ)

Posted by Karen Goldfarb

October 21, 2020 at 6:14 PM

Crystal Research Associates has issued an 84-page Updated Executive Informational Overview (EIO) on clinical-stage biotechnology company, GeoVax, Labs Inc. (GOVX-NASDAQ), detailing the Company's recent news and developments, anticipated clinical trial and regulatory filing milestones, and financial position. The report is available for download below.

Download GeoVax Labs, Inc.  Updated Base Report 10-21-2020

Read More

Topics: geovax

July 2020 Update on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE)

Posted by Karen Goldfarb

July 10, 2020 at 12:15 PM

Crystal Research Associates has issued an 11-page Quarterly Update on specialty biotech pharmaceutical research and development (R&D) company, FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), detailing the Company's recent news and developments—including its recent permission from the U.S. FDA on June 1, 2020 to submit an Investigational New Drug Application (IND) to use FSD201 to treat COVID-19 (the disease caused by the SARS-CoV-2 virus)—as well as its recent financial position. The report is available for download below.

Download FSD Pharma Inc.  Update

Read More

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), ultramicronized-PEA, fsd, FSD201, medical cannabis, covid19, coronovirus

New Research Released on CEL-SCI Corporation (CVM-NYSE)

Posted by Karen Goldfarb

June 3, 2020 at 12:34 PM

An Executive Informational Overview (EIO) is now available on CEL-SCI Corporation, a clinical-stage biotechnology company developing immunotherapy technologies to treat cancer, autoimmune, and infectious diseases. The 86-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download CEL-SCI Corporation Report

Read More

Topics: biotech, immunotherapy, CEL-SCI, infectious diseases, leaps, cancer, autoimmune, head and neck cancer, squamous cell carcinoma, rheumatoid arthritis, covid19, cervical dysplasia

New Research Released on StageZero Life Sciences, Ltd (SZLS-TSX)

Posted by Karen Goldfarb

April 9, 2020 at 12:33 PM

An Executive Informational Overview (EIO) is now available on StageZero Life Sciences, Ltd (SZLS-TSX), a revenue-generating innovator in the liquid biopsy space, dedicated to the early detection of cancer and multiple disease states. The 72-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download StageZero Life Sciences  Report

Read More

Topics: liquid biopsy, blood-based diagnostics, ColonSentry, Sentinel Principle, EarlyCDT®-Lung, BreastSentry, StageZero Life Sciences

New Research Released on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE)

Posted by Karen Goldfarb

March 11, 2020 at 2:27 PM

An Executive Informational Overview (EIO) is now available on FSD Pharma Inc. (HUGE-NASDAQ/HUGE-CSE), a specialty biotech pharmaceutical company focused on developing FDA-approved synthetic compounds targeting the endocannabinoid system (ECS) of the human body. The 68-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

Download FSD Pharma Inc.  Initiation Report

Read More

Topics: Cannabis, fsd pharma, Endocannabinoid System (ECS), Palmitolylethonalamide (PEA), Prismic Pharmaceuticals, ultramicronized-PEA, fsd, SciCann Therapeutics, Solarvest BioEnergy Inc., FSD201, medical cannabis, Canntab Therapeutics Ltd, Huge Shops, Aura Health Inc.

New Research Released on Reliance Global Group, Inc. (RELI-OTC)

Posted by Karen Goldfarb

July 5, 2019 at 1:58 PM

An Executive Informational Overview (EIO) is now available on Reliance Global Group, Inc. (RELI-OTC), a diversified holding company investing in real estate and insurance markets. The 48-page report details the Company's business, its strategy, market opportunities, strategic relationships, competition, financials, risks, and more. It is available for download below.

VIEW REPORT

Read More

Topics: reliance global group, multi-family properties, insurance, insurance carriers, Employee Benefit Solutions, The Referral Depot, reliance global holdings, RELI, insurance agencies, REIT, real estate, U.S. Benefits Alliance, Commercial Solutions of Insurance Agency, Southwestern Montana Insurance Center, Fortman Insurance Agency

Receive Our Research Notifications

About This Blog

We provide investor-based research and corporate communications services to companies worldwide. Visit our About Us page to learn more.

Posts by Date

see all

Posts by Topic